Madrigal Pharmaceuticals (MDGL) EBIT Growth (3y) (2013 - 2026)

Madrigal Pharmaceuticals (MDGL) EBIT Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 16.96%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 38.78%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 13.47%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -12.10%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 69.02%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Madrigal Pharmaceuticals 15.77 Bn 15.54 Bn - -5.78%

Historic Data

Download Data
DateValue
Mar 31, 2026 -5.78%
Dec 31, 2025 11.26%
Sep 30, 2025 -12.33%
Jun 30, 2025 12.42%
Mar 31, 2025 -11.26%
Dec 31, 2024 -1.22%
Sep 30, 2024 -22.57%
Jun 30, 2024 -38.08%
Mar 31, 2024 -42.11%
Dec 31, 2023 -25.31%
Sep 30, 2023 -18.79%
Jun 30, 2023 -19.76%
Mar 31, 2023 -27.26%
Dec 31, 2022 -41.74%
Sep 30, 2022 -49.23%
Jun 30, 2022 -45.73%
Mar 31, 2022 -47.03%
Dec 31, 2021 -64.72%
Sep 30, 2021 -77.30%
Jun 30, 2021 -99.07%